Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析

◆英語タイトル:Fate Therapeutics Inc (FATE) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15509
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Fate Therapeutics Inc (FATE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company’s immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc Key Recent Developments

Mar 18,2019 Fate Therapeutics announces the appointment of Karin Jooss, Ph.D. to its board of directors
Mar 05,2019 Fate Therapeutics reports fourth quarter and full year 2018 financial results and highlights operational progress
Feb 20,2019 Fate Therapeutics names Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
Dec 04,2018 12/4/18 – Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Fate Therapeutics Inc – Key Facts
Fate Therapeutics Inc – Key Employees
Fate Therapeutics Inc – Key Employee Biographies
Fate Therapeutics Inc – Major Products and Services
Fate Therapeutics Inc – History
Fate Therapeutics Inc – Company Statement
Fate Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Fate Therapeutics Inc – Business Description
R&D Overview
Fate Therapeutics Inc – Corporate Strategy
Fate Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Fate Therapeutics Inc – Strengths
Fate Therapeutics Inc – Weaknesses
Fate Therapeutics Inc – Opportunities
Fate Therapeutics Inc – Threats
Fate Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Fate Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 18, 2019: Fate Therapeutics announces the appointment of Karin Jooss, Ph.D. to its board of directors
Mar 05, 2019: Fate Therapeutics reports fourth quarter and full year 2018 financial results and highlights operational progress
Feb 20, 2019: Fate Therapeutics names Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
Dec 04, 2018: 12/4/18 – Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
Nov 30, 2018: Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy
Nov 01, 2018: Fate Therapeutics reports third quarter 2018 financial results and highlights operational progress
Oct 04, 2018: Fate Therapeutics names Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations
Aug 06, 2018: Fate therapeutics announces second quarter 2018 financial results and highlights operational progress
May 10, 2018: Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
Mar 05, 2018: Fate Therapeutics Announces Fourth Quarter 2017 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Fate Therapeutics Inc, Key Facts
Fate Therapeutics Inc, Key Employees
Fate Therapeutics Inc, Key Employee Biographies
Fate Therapeutics Inc, Major Products and Services
Fate Therapeutics Inc, History
Fate Therapeutics Inc, Subsidiaries
Fate Therapeutics Inc, Key Competitors
Fate Therapeutics Inc, Ratios based on current share price
Fate Therapeutics Inc, Annual Ratios
Fate Therapeutics Inc, Annual Ratios (Cont...1)
Fate Therapeutics Inc, Interim Ratios
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Fate Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Fate Therapeutics Inc, Performance Chart (2014 - 2018)
Fate Therapeutics Inc, Ratio Charts
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ergon, Inc.:石油・ガス:M&Aディール及び事業提携情報
    Summary Ergon Inc (Ergon) is an integrated energy company that carries out the exploration and production of crude oil and natural gas, processing, transportation and terminaling of crude oil, storage, marketing and distribution of specialty petroleum products. The company also manufactures and mark …
  • Chubb Limited:企業の戦略・SWOT・財務情報
    Chubb Limited - Strategy, SWOT and Corporate Finance Report Summary Chubb Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lukoil Oil Co (LKOH):企業の財務・戦略的SWOT分析
    Lukoil Oil Co (LKOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Citibank Berhad:企業の戦略的SWOT分析
    Citibank Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Kuwait Gulf Oil Co:企業の戦略的SWOT分析
    Kuwait Gulf Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • ICBC Standard Bank Plc:企業の戦略・SWOT・財務情報
    ICBC Standard Bank Plc - Strategy, SWOT and Corporate Finance Report Summary ICBC Standard Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mylan Pharmaceuticals Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mylan Pharmaceuticals Pvt Ltd (Mylan), a subsidiary of Mylan NV, is a pharmaceutical company that manufactures generic, speciality and active pharmaceutical ingredients (API). The company provides products such as critical care products, hepato care products, HIV care products, onco care pro …
  • Dr. Reddy’s Laboratories Ltd (DRREDDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestina …
  • Bioasis Technologies Inc (BTI):医療機器:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Schroders Private Bank:企業の戦略・SWOT・財務情報
    Schroders Private Bank - Strategy, SWOT and Corporate Finance Report Summary Schroders Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Arlington Asset Investment Corp (AI):企業の財務・戦略的SWOT分析
    Summary Arlington Asset Investment Corp (AAIC) is an investment firm that offers asset management and investment services. The firm acquires and holds mortgage-related assets. It acquires residential mortgage-backed securities issued by the US government agencies. AAIC also acquires mortgage-backed …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066):企業の財務・戦略的SWOT分析
    Shandong Weigao Group Medical Polymer Company Ltd (1066) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • BBVA Banco Frances S.A. (FRAN3):企業の財務・戦略的SWOT分析
    BBVA Banco Frances S.A. (FRAN3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Sanofi India Ltd (SANOFI):企業の財務・戦略的SWOT分析
    Summary Sanofi India Ltd (Sanofi India), formerly Aventis Pharma Ltd, a subsidiary of Sanofi is a healthcare company. It manufactures and markets pharmaceutical and prescription products. The company offers products in the form of capsules, tablets, injection, vials, ampoules, ointments, creams and …
  • MAX Resource Corp. (MXR):企業の財務・戦略的SWOT分析
    MAX Resource Corp. (MXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Danaher Corp (DHR):企業の財務・戦略的SWOT分析
    Danaher Corp (DHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • California Physicians’ Service:企業の戦略的SWOT分析
    California Physicians' Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Engie SA (ENGI):電力:M&Aディール及び事業提携情報
    Summary Engie SA (Engie) is an electric utility. It provides electricity, natural gas, and energy services. It generates electricity from hydro, wind, biomass, and solar sources, and trades and sells that energy; supplies, distributes, trades, and sells natural gas; and offers a comprehensive range …
  • Caltex Australia Ltd (CTX)-石油・ガス分野:企業M&A・提携分析
    Summary Caltex Australia Limited (Caltex) is a transport fuel supplier and convenience retailer. It is the parent company of Caltex group. The company purchases, refines, distributes and markets petroleum products. It owns and operates refinery, convenience stores, road tankers, storage terminals, s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆